Status: Not yet recruiting
Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease
Primary Objective: To assess the safety profile of autologous MitoCell administered to subjects with idiopathic Parkinson's disease (PD) Secondary Objective: To explore the efficacy and safety of MitoCell given as the recommended dose by stereotactic intrastriatal implantation
Participants needed: 9
Trial details
Phase: Phase 1Age: 45-70Biological sex: AllType: InterventionalSponsor: Taiwan Mitochondrion Applied Technology Co., Ltd.Updated: Nov 21, 2024
Eligibility criteria
Provision of signed and dated informed consent form [+9]
Atypical or secondary Parkinsonism [+34]